Gene Therapy Company Reveals Promising Results From Huntington's Disease Clinical Trials
Positive Interim Data Update: Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease.
Disclaimer: This article is for informational purposes only and does not constitute an endorsement or recommendation. All clinical trial outcomes and statements are subject to further validation and regulatory review. Readers should consult healthcare professionals for medical advice.
Real-time information is available daily at ht…